Drug intelligence / Profile preview

Yangxin Shengmai

Development stage: Phase 4
Lead developer: Guang'anmen Hospital
Modality: Small Molecules
Administration: Oral

Overview

Yangxin Shengmai is a Traditional Chinese Medicine (TCM) formulation, typically prepared as granules, used for the treatment of cardiovascular conditions including stable angina pectoris and coronary heart disease. It is specifically indicated for patients diagnosed with Qi-Yin deficiency syndrome according to TCM principles. The formulation is designed to nourish the heart and restore the pulse, aiming to improve myocardial blood supply and alleviate symptoms of chest pain and palpitations. It is currently being evaluated in Phase 4 clinical trials led by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences to further establish its efficacy and safety profile in the Chinese population.

Brand names: Yangxin Shengmai Granules
Other names: Yangxin Shengmai Keli

Beyond the preview

Go deeper on Yangxin Shengmai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangxin Shengmai.

Explore the full profile